New funding to accelerate commercialisation
ProteomEdge has successfully closed a 7.8 million SEK funding round, led by Navigare Ventures — a subsidiary of Wallenberg Investments AB — with strong participation from existing shareholders.
This investment fuels our mission to deliver a cutting-edge analytical platform for absolute protein quantification using mass spectrometry. Our growing portfolio of proprietary products, targeting clinically relevant plasma biomarkers such as apolipoproteins, complement factors, and liver biomarkers, is already making impact in key research areas.
“This investment will enable us to expand our proprietary product line of internal standards for mass spectrometry platforms and bring them to market faster.” — Professor Mathias Uhlén, Co-founder and Chairman of the Board
Welcoming Dr. Henrik Everberg as CEO
We are pleased to welcome Dr. Henrik Everberg as our new full-time Chief Executive Officer, starting August 2025. Dr. Everberg brings two decades of experience in the life science sector, with leadership roles at PhaDia, Atlas Antibodies, and most recently as COO of Pixelgen Technologies.
He succeeds Dr. Marianne Hansson, who has served as part-time CEO during our formative phase. We extend our sincere thanks to Dr. Hansson for her impactful leadership.